Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?

Kissei Pharmaceutical forecasts a 5.1% decline in sales for the fiscal year ending March 2013. This year’s NHI price revision has had a hard impact on the company, which has only a limited number of new products likely to contribute...read more